Nova Eye Medical (ASX:EYE) — Material Events

ASX:EYE · 7 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 7 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
7
Nova Eye Medical’s Sales Surge 32%, Eyes China Market with New ApprovalMedium
Nova Eye Medical Q1 FY26 sales up 32%, iTrack™ Advance approved in China, EBITDA breakeven expected H2 FY26
31 Oct 2025 ·Quarterly Activities and Cashflow Report ·85
Nova Eye Medical Surges with Record US$6.1M Quarter, US Market Leads GrowthMedium
Nova Eye Medical posts record US$6.1M quarterly sales, 24% annual growth, driven by US market
12 Jan 2026 ·Sales Update ·85
Nova Eye Medical Narrows EBITDA Loss with 23% Sales Growth and New US Product FeatureMedium
Nova Eye Medical posts 23% sales growth, narrows EBITDA loss, and launches new product feature
29 Apr 2026 ·Quarterly Activities and Cashflow Report ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.

Market Mentions 4 - appeared in market wrap coverage